Last call for registrations to Pre-Filled Syringes East Coast conference

SMi Group8 - 9 April 2019, Boston, USA.
SMi's global portfolio of events on Pre-Filled Syringes secured an audience of over 300 senior drug delivery and medical device experts over the last year. Next week will be held the 6th annual Pre-Filled Syringes East Coast conference and exhibition where industry leaders from pharmaceutical, biotech and device manufacturing, meet to get updates on medical devices advances, parenteral drug delivery, share experiences and network. Organisers encourage everyone involved in the industry not to miss out on this premier platform as only limited number of delegate places remain. For those interested in attending, contact Kieran Ronaldson on +44 (0) 20 7827 6744 or book on the Pre-Filled Syringes East Coast conference website.

Event in brief: Over 25 presentations from a mix of leading industry players and big pharma such as - Shire, Merck, FDA, Janssen, Steri-Tek, Biogen, Sanofi, Eli Lilly, Zeon and many others.

Organisations who have recently secured some of the last few remaining places includeAmerican Regent, Credence MedSystems, Dechra, Imbrium Therapeutics, Nipro Pharma Packaging, Pfizer,Purdue Pharma, Plastic Ingenuity, Sumitomo Rubber North America, Uhlmann, W.L Gore. List of attendees available on the event website.

Over 15 exhibition stands will help navigate through supplier offers: 3P Innovation, Aptar Pharma, CSS (CONNECTICUT SPRING & STAMPING),HarroHöfliger, LONSTROFF, MITSUBISHI GAS CHEMICAL, NN Life Sciences, Owen Mumford, PHC Corporation of North America, Polyplastics, RheoSense, SCHOTT, Steri-Tek, SUMITOMO RUBBER INDUSTRIES, West Pharmaceutical Services and ZEON

To register for one of the last remaining delegate places, either call Kieran Ronaldson on +44 (0) 20 7827 6744 or book online at www.pfsamericas.com

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...